Brii Biosciences Revenue and Competitors

Location

$415M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Brii Biosciences's estimated annual revenue is currently $20.8M per year.(i)
  • Brii Biosciences's estimated revenue per employee is $155,000
  • Brii Biosciences's total funding is $415M.
  • Brii Biosciences's current valuation is $1.4B.

Employee Data

  • Brii Biosciences has 134 Employees.(i)
  • Brii Biosciences grew their employee count by -4% last year.

Brii Biosciences's People

NameTitleEmail/Phone
1
Co-Founder and CEOReveal Email/Phone
2
SVP, Head Patient Advocacy & PolicyReveal Email/Phone
3
VP, Head IT and Data SciencesReveal Email/Phone
4
Head DiscoveryReveal Email/Phone
5
Head China R&DReveal Email/Phone
6
Head CNS Diseases Therapy AreaReveal Email/Phone
7
VP Clinical Operations and SciencesReveal Email/Phone
8
VP Pharmaceutical SciencesReveal Email/Phone
9
Associate DirectorReveal Email/Phone
10
Sr. Director, Clinical ResearchReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.2M72-13%N/AN/A
#2
$5099.8M32902-4%N/AN/A
#3
$1.7M110%N/AN/A
#4
$0.6M4-56%N/AN/A
#5
$0.9M11-39%N/AN/A
#6
$1.7M1110%N/AN/A
#7
$0.6M4-33%N/AN/A
#8
$4.8M31-6%N/AN/A
#9
$6.4M413%N/AN/A
#10
$4.2M27-18%N/AN/A
Add Company

What Is Brii Biosciences?

Brii Biosciences (Brii Bio) is a company committed to serving patients? needs and improving public health in China. Founded in early 2018, the company focuses on accelerating innovation and optimizing access to the latest medicines for Chinese patients. Brii Bio helps global partners drive growth and improve return on investment through better understanding of Chinese healthcare systems and access to the world?s second largest pharmaceutical market. The company?s focus is treatments for chronic illnesses with significant burdens, including infectious diseases, liver and lung diseases, and other illnesses. The company is headquartered in the People?s Republic of China and the United States, with offices in Shanghai, Beijing, San Francisco, and Durham, North Carolina.

keywords:N/A

$415M

Total Funding

134

Number of Employees

$20.8M

Revenue (est)

-4%

Employee Growth %

$1.4B

Valuation

N/A

Accelerator

Brii Biosciences News

2022-04-06 - China Kintor's COVID drug candidate cuts hospital, death risk ...

China has approved Pfizer Inc's Paxlovid and Brii Biosciences Ltd's antibody-based medicine for mild and moderate COVID patients with high...

2022-03-30 - Brii Bio Presents New Data on BRII-835 (VIR-2218) in ...

Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022. (PRNewsfoto/Brii Biosciences...

2022-03-30 - Brii Bio Announces Strategic Partnership with Sinopharm to ...

Brii Biosciences Limited ("Brii Bio", stock code: 2137.HK) is a biotechnology company based in China and the United States committed to...

2021-11-17 - Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit

BEIJING and DURHAM, N.C., Nov. 17, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced it has r ...

2021-09-28 - Brii Biosciences : Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy

DURHAM, N.C. and BEIJING, Sept. 27, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced the app ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$18.8M13440%N/A
#2
$20.8M1349%N/A
#3
$19.7M1366%N/A
#4
$3.5M136-9%N/A
#5
$28.1M13710%N/A